Hemophilia A
Conditions
Interventions
Repatumab group:Repertumab was administered intravenously.
Repatumab + bortezomib group:Intravenous administration of repatumab in conjunction with subcutaneous injection of bortezomib
Sponsors
The Second Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
14 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. There is no evidence of a bleeding tendency. 2. The patient has a prior diagnosis of hemophilia A and a history of coagulation factor VIII infusions. 3. Laboratory findings indicate prolonged APTT, whereas PT, TT, Fib, PLT, von Willebrand factor antigen (VWF:Ag), and VWF activity (VWF:Act) remain within normal limits. 4. Factor VIII activity (FVIII:C) is less than 5%. 5. The Bethesda assay confirmed the presence of FVIII inhibitors with a titer exceeding 0.6 BU/ml.
Exclusion criteria
Exclusion criteria: 1. Patients diagnosed with acquired hemophilia A; 2. Hemophilia A patients with inhibitors who present with life-threatening non-hematological conditions; 3. Patients with uncontrolled infections, active hepatitis, or severe immunodeficiency diseases such as AIDS; 4. Patients known to be allergic to any CD20 monoclonal antibody, murine proteins, or any excipient in repatol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Coagulation factor ? activity;Coagulation factor ? inhibitor titer; | — |
Secondary
| Measure | Time frame |
|---|---|
| monthly bleeding rate; | — |
Countries
China
Contacts
Public ContactJing-yu Zhang
The Second Hospital of Hebei Medical University
Outcome results
None listed